Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically ...

Reports Q2 revenue $5,000 vs $5,000 last year. “Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive ...

Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent ...

If you suffered purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly ...

Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors ...

On June 26, 2025, Altimmune issued a press release announcing "topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH)." ...

Altimmune has a mixed earnings surprise history, beating estimates in three of the trailing four quarters and missing the ...

Altimmune's pemvidutide showed strong MASH resolution and good tolerability in IMPACT, but fibrosis data fell short. See why ALT stock is downgraded to hold.

The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, AUD, ALD and obesity. For more information, please visit www.altimmune.com.

The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, AUD, ALD and obesity. For more information, please visit www.altimmune.com.